To assess the impact of a novel molecular imaging technique, 68 Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/ computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with curative intent.
Objective
To assess the impact of a novel molecular imaging technique, 68 Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/ computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with curative intent.
Patients and Methods
In all, 131 consecutive patients were referred to our centre for a 68 Ga-PSMA PET/CT in the setting of recurring prostate cancer. Of these patients, 11/131(8%) presented with persistent PSA after radical prostatectomy, while 120/131 (92%) were referred for biochemical recurrence after surgery, radiotherapy or both. The images where taken 1 h after injection of 2 MBq/kg of the 68 Ga-(HBED-CC)-PSMA ligand. All examinations were interpreted by two experienced nuclear medicine specialists. Using the results of the examination, a multidisciplinary oncology committee (MOC) reported on the treatment strategy. A positive impact on clinical management was considered if the examination determined a modification in the treatment strategy compared to the MOC decision before PSMA imaging.
Results
All patients completed the examination with no adverse reactions. The median (interquartile range) PSA level at the time of the examination was 2.2 (0.72-6.7) ng/mL. Overall, 68 Ga-PSMA PET/CT detected at least one lesion suspicious for prostate cancer in 98/131 (75%) patients. There was an impact on subsequent management in 99/131 patients (76%). The main modifications included continuing surveillance (withholding hormonal therapy), hormonal manipulations, stereotaxic radiotherapy, salvage radiotherapy, salvage node dissection or salvage local treatment (prostatectomy, highintensity focussed ultrasound).
Introduction
Prostate cancer is the most common malignancy in men and accounts for >26 000 deaths yearly in the USA [1] . Although most patients present with organ-confined disease,~21% of them will develop a biochemical recurrence (BCR) after primary treatment [2] . To date, although PSA remains an extremely accurate biomarker for recurrence, its values cannot determine the recurrence location and burden of recurrent disease. Clearly, these findings are crucial in defining the management of recurrent prostate cancer: while local relapses and oligometastatic states can be targeted by focal treatment, including stereotaxic radiotherapy, salvage surgery or highintensity focussed ultrasound (HIFU); high-volume metastases require systemic treatment via hormonal manipulations or chemotherapy [3] . To date, conventional imaging studies such as CT, bone scintigraphy and MRI have had a low diagnostic yield in patients with BCR, especially those with low PSA levels (<20 ng/mL), which represent the vast majority of cases [4] .
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C-choline positron emission tomography (PET) has been intensely investigated in this scenario with variable results, but its sensitivity is strongly dependent on PSA level and kinetics with low detection rates for PSA levels of <1 ng/mL [5] . 68 Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) PET/CT scan is a novel molecular imaging technique in the field of prostate cancer, and is currently being tested in different clinical scenarios [6] [7] [8] . The test relies on the overexpression of PSMA by prostate cancer cells. PSMA is a transmembrane type II glycoprotein, also called folate hydrolase I or glutamate carboxipeptidase II, found both in local and metastatic prostate cancer cells [9, 10] . Recently, Schwenck et al. [11] compared 68 Ga-(HBED-CC)-PSMA to 11 C-choline PET in 67 men with recurrent prostate cancer: the authors reported a higher sensitivity of the former examination, especially at low PSA levels, for both lymph node and bone metastases detection.
In our tertiary referral centre 68 Ga-PSMA PET/CT has recently been introduced, being the first centre in Belgium and we are performing this test in patients presenting with a BCR after primary treatment of prostate cancer with curative intent. The aim of the present study was to retrospectively evaluate the clinical impact of 68 Ga-PSMA PET/CT in these patients, according to the influence of the test on the treatment decision-making in the setting of recurrent prostate cancer. As in our centre decisions on every patient with cancer are made by a multidisciplinary oncology committee (MOC), we decided to explore the impact of the results of 68 Ga-PSMA PET/CT on management strategy and treatment modifications based on this multidisciplinary approach.
PET tracer relies on the overexpression of prostate-specific membrane antigen (PSMA), a transmembrane folate hydrolase, on the surface of PCa cells. This overexpression has been demonstrated both locally and in regional or metastatic lesions within lymph nodes, soft tissue and bone [12] ; therefore, imaging with radiolabelled 68 Ga-PSMA has the potential to detect lymph node or local recurrence and/or to exclude distant metastases. This new PET tracer relies on the overexpression of prostate-specific membrane antigen (PSMA), a transmembrane folate hydrolase, on the surface of PCa cells. This overexpression has been demonstrated both locally and in regional or metastatic lesions within lymph nodes, soft tissue and bone [12] ; therefore, imaging with radiolabelled 68 Ga-PSMA has the potential to detect lymph node or local recurrence and/or to exclude distant metastases.
Patients and Methods
Beginning in January 2015 to December 2015, 154 patients referred to our tertiary centre to have a 68 Ga-PSMA PET/CT were retrospectively analysed. The study was approved by the Ethics Committee of the Jules Bordet Institute, Bruxelles, Belgium and received Institutional Review Board approval. We excluded from our analysis 20 patients in whom the examination was performed for initial local staging, two in whom the examination was done after treatment of castration-resistant prostate cancer, and one in whom the test was used to characterise a lymphadenopathy (ultimately revealed as bladder cancer in origin). This resulted in a cohort of 131 for final analysis. All patients underwent 68 Ga-PSMA PET/CT because of a BCR or disease progression of prostate cancer after local treatment with curative intent. General characteristics of the cohort are given in Table 1 . In all, 11/131 (8%) patients had persistent PSA after radical prostatectomy, while 120/131 (92%) had BCR after surgery, radiotherapy, HIFU or a combination of treatments. BCR after surgery was defined by a PSA level of >0.2 ng/mL and subsequent rise [3] . After radiotherapy, HIFU or brachytherapy the Phoenix criteria (nadir + 2 ng/mL) were used to define BCR [13] . PSA was measured before PSMA PET/CT testing and had a median [interquartile range (IQR)] value of 2.2 (0.72-6.7) ng/mL. The vast majority of patients had undergone radical prostatectomy as their primary treatment (106/131, 81%), followed by external beam radiation therapy (17/131, 13%). In all, 26/131 patients had already undergone a 11 C-choline PET in another institution in the 6 months prior to 68 Ga-PSMA PET/CT: in these cases the images of the two scans were compared by our nuclear medicine specialists at the time of the PSMA PET examination. The patient's case was discussed in a MOC only after the 68 Ga-PSMA-PET/CT results were available. At least one urologist, one medical oncologist, one pathologist, one radiation oncologist and one nuclear medicine specialist were always present during such meetings. 68 Ga-PSMA PET/CT was considered of clinical utility when its results, positive or negative, determined a modification of a pre-planned
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© 2016 The Authors BJU International © 2016 BJU International therapeutic strategy or the addition of a new therapy. This included focal treatment of oligometastases, continuing surveillance, withholding androgen-deprivation therapy (ADT), and early chemotherapy in high-volume metastatic disease. 68 
Ga-PSMA PET/CT Details and Interpretation
Images were acquired at the Jules Bordet Institute using a General Electric (GE) Discovery 690 time of flight (TOF) PET system, 60 min after injection (range 60-70 min) of 2 MBq/kg of 68 Ga-labeled HBED-CC (with a maximum of 200 MBq). 68 Ga was obtained after elution from a 68Ge/68Ga radionuclide generator (IGG100; Eckert & Ziegler, Seneffe, Belgium). All PET scans were acquired in three-dimensional mode with an acquisition time of 120 s/bed position with an overlap of 23.4%. PET images were reconstructed with the built-in GE VUE Point Fx algorithm, a sharper resolution recovery algorithm, an ordered subset expectation maximisation algorithm with three iterations and 18 subsets, and were post-filtered with a 6.8-mm full-width at halfmaximum (FWHM) Gaussian function. The images were corrected for attenuation and for scatter using the CT data. CT was performed with a 64-slice helical scanner (VCT; GE Medical Systems, Chicago, IL, USA). The tension was 120 kV, and the current was modulated by the Auto-mA software with a noise index of 30 (range 30-200 mA) and ASIR â . The other CT acquisition parameters were 0.5 s/CT rotation and a pitch of 0.98. The CT images were reconstructed with the ASIR algorithm set at 40%, with a matrix of 512 9 512 (0.97 9 0.97 mm pixel size) and a slice thickness of 2.5 mm. The PET matrix was 192 9 192 pixels of 2.73 9 2.73 mm with a slice thickness of 3.27 mm.
Two experienced nuclear medicine physicians (C.A., P.F.) read independently all PSMA PET-CT images on a dedicated workstation (Advantage Workstation; GE Healthcare, Chicago, IL, USA) using the commercial PET VCAR software AW Server 3.2.
Any focal uptake of 68 Ga-PSMA ligand at least twice that of the surrounding background and not associated with physiological uptake was considered suggestive for malignancy.
Statistical Analysis
Descriptive statistics were used to analyse our outcome data. Differences in positive examination rates across various PSA levels were explored via the chi-squared test. The difference in the median PSA level across groups in whom 68 Ga-PSMA PET/CT did and did not modify treatment strategy was explored with the Mann-Whitney test. All analyses and graphics were performed using the STATA software version (STATA Corp, Texas, USA) 12. A two-sided P < 0.05 was defined as statistically significant.
Results
All 131 men completed the examination with no adverse events. Overall, 68 Ga-PSMA PET/CT was positive for at least one lesion suspicious for prostate cancer metastasis in 98/131 patients (75%). As shown in Fig. 1 , PSMA results were significantly more likely to be positive with increasing values of PSA (P < 0.001), and in all patients with PSA levels of ≥10 ng/ mL at least one lesion was detected. Indeed, 68 Ga-PSMA PET/ CT was found to be positive in 45% of patients with a PSA level of <0.5 ng/mL, in 75% of men with PSA level of 0.5-1 ng/mL, in 83% of men with PSA levels of 1-3.99 ng/mL and in 95% of those men with a PSA level of 4-9.99 ng/mL. Ga-PSMA PET/CT discussed in the MOC determined modification in treatment strategy in 99/131 (76%) men, modifying the first proposed therapeutic approach. Of these 99 patients, 68 had a positive while 31 had a negative 68 Ga-PSMA PET/CT scan. The modifications are listed in Table 2 : indeed the most common decision was to avoid ADT (63/99, 64%) and undergo clinical surveillance (22/99, 22%), stereotaxic radiotherapy (12/99, 12%) or salvage radiotherapy (11/99, 11%). Salvage radiotherapy was avoided in 22/99 (22%) men, in favour of surveillance, ADT or salvage node dissection ( Table 2) . ADT was instead implemented in 13/99 (13%) patients initially planned for local treatment or surveillance. Treatment of oligometastatic disease was proposed and performed in 34 men (14 men underwent stereotaxic radiotherapy, 10 salvage lymph node dissection, 8 salvage HIFU and 2 salvage prostatectomy).
Concerning the 32/131 (24%) patients in whom the PSMA PET/CT did not modify the planned treatment, this group included 11/32 (34%) men in whom pelvic irradiation was already planned; in these patients PSMA PET/CT confirmed the local recurrence that had either already been seen on MRI or suspected according to predictive factors (Table 3) [3] . In 16/32 (50%) men, a complete androgen blockage was already planned given a rapidly ascending PSA, and confirmed by the PSMA PET/CT due to detection of multiple metastases or because of the patient being unfit for focal treatment of oligometastases. Finally, in two patients in whom a stereotaxic radiotherapy was proposed, the dosimetric CT was unable to identify the target lesion and as such it was not possible to deliver the treatment. Of note, the PSA level did not differ significantly (P = 0.14) across patients in whom PSMA PET/ CT did or did not modify treatment strategy.
Discussion
BCR can occur in over one-third of patients after primary treatment for prostate cancer [14] , with most of these men then developing clinical metastases within 5-8 years. As to date most imaging examinations are unable to identify the lesion responsible for the PSA recurrence at an early stage with low PSA levels, men are frequently treated by systemic hormonal castration, with heavy metabolic consequences, reduced quality of life, and possibly increased cardiovascular mortality [15] . Moreover, the identification of a low-volume metastatic state, or oligometastases, may prompt the use of Ga PSMA PET/CT results according to PSA level. Table 2 Treatment modifications according to 68 Ga-PSMA PET/CT results in 99 patients.
Planned treatment (n)
Modification according to PSMA Total patients, n
ADT (22) Salvage radiotherapy (7) Surveillance 29
Salvage radiotherapy (7) Salvage HIFU (3) Antiandrogen monotherapy (1) Stereotaxic radiotherapy (1) Surveillance (1) ADT 13
ADT ( focal treatments [16] , reducing morbidity, delaying hormone treatment and possibly improving oncological outcomes. In this scenario, an accurate diagnostic tool, capable of guiding treatment, is of crucial importance and can significantly modify our conception and management of recurrent prostate cancer [17] . In the present study, we evaluated the real-life, clinical utility of performing a 68 Ga-PSMA PET/CT in patients with BCR after primary treatment of prostate cancer. The test was useful in 76% of patients determining an impact on therapeutic decision-making. Moreover, even in those patients in whom the results of the imaging test did not modify the management, they frequently confirmed the decided strategy, supporting the multidisciplinary decisionmaking process. 68 Ga-PSMA PET/CT is a novel molecular imaging technique currently being explored in the field of prostate cancer. Fendler et al. [12] evaluated the test in the local staging of prostate cancer, and found that 68 Ga-PSMA PET detected seminal vesicle invasion with a 86% accuracy and extracapsular extension with a 71% accuracy. Moreover, 68 Ga-PSMA PET/CT may be used in combination with multiparametric MRI in the local staging of prostate cancer, increasing specificity and positive predictive value for significant cancer, as reported by Rhee et al. [18] . Concerning clinical management and decision making, Dewes et al. [19] analysed 15 patients who were scheduled to undergo definitive local radiotherapy. They reported a change in clinical TNM stage in 8 of the 15 patients, and a modification of irradiation plan in 5 of the 15 patients, mainly concerning lymph node irradiation. Morigi et al. [20] performed a prospective trial on 38 men who underwent both 68 Ga-PSMA and 18F-fluoromethylcholine PET in the setting of PSA recurrence after primary treatment of prostate cancer. In patients with low PSA levels (0.5-2 ng/mL), detection rate was 69% for 68 Ga-PSMA vs 31% for 18 F-fluoromethylcholine. Moreover, the authors reported an impact of the tests on clinical management in 63% of the patients, mainly due to the results of 68 Ga-PSMA PET. Rauscher et al. [21] evaluated the accuracy of 68 Ga-PSMA PET compared to morphological imaging to assess lymph node metastases in patients with recurrent prostate cancer. In all, 48 men underwent preoperative 68 Ga-PSMA PET and then salvage lymphadenectomy: 68 Ga-PSMA PET detected lymph node metastases in 53/68 (77.9%) pathologically confirmed metastatic lymph node fields, while morphological imaging was positive in only 18/67 (26.9%). Moreover, the lymph nodes detected by 68 Ga-PSMA PET were smaller (mean 8.3 mm) compared to those detected by conventional CT or MRI (mean 13 mm). Similarly, Giesel et al. [22] reported a significant increase in the detection of pathological pelvic lymph nodes in 21 patients with recurrent prostate cancer via a 68 Ga-PSMA PET examination compared to conventional imaging: 66% of patients identified by 68 Ga-PSMA PET in fact were negative on conventional imaging modalities.
In the setting of recurrent prostate cancer, the largest studies to date have been published by Afshar et al. [23] and by Eiber et al. [24] , reporting promising results in 319 and 248 men, respectively. In the first study, the investigators retrospectively analysed 68 Ga-PSMA PET results in 319 men with recurrent prostate cancer: the examination detected at least one lesion in 83% of cases and, in the subset for which histology was available, the authors described a sensitivity of 77% and a specificity of 100%. Lesion detection was correlated to PSA level at the time of the examination. Eiber et al. [24] retrospectively evaluated 248 men with prostate cancer recurrence after radical prostatectomy; 90% had at least one suspicious lesion and a positive correlation with serum PSA level was also found, as in the present study.
In addition, multiple case reports have documented the utility of 68 Ga-PSMA PET/CT in the identification of oligometastatic prostate cancer [25, 26] ; nonetheless, different pathological conditions can present with PSMA uptake leading to false positives [27] . Finally, Pyka et al. [28] compared PSMA PET to bone scintigraphy in the detection of bone metastases. In their study examining 126 men (of which 76 were diagnosed with metastatic bone disease), PSMA PET significantly outperformed bone scintigraphy, with overall sensitivity and specificity of 98.7-100% and 88.2-100%, compared to 86.7-89.3% sensitivity and a 60.8-96.1% specificity of bone scintigraphy (P < 0.001).
In the present study, 68 Ga-PSMA PET/CT detected at least one lesion suspicious for prostate cancer recurrence in 75% of our patients. This is consistent with previously reported data in men with recurrent prostate cancer, with detection rates ranging from 71 to 89.5% [12, 18] , although detection remains dependent on PSA levels at the time of PET examination [29, 30] . Of note, 20% of our present patients had PSA levels of <0.5 ng/mL, and half of those who overall presented a negative scan were within this group. It remains poorly understood why some patients have negative PSMA examinations, as nearly all prostate cancers express PSMA [31] : different hypotheses include dedifferentiated neuroendocrine cancers, recurrences situated close to the urinary tract and millimetric recurrences below the resolution of the PET scans [23] . In the present study, we focused our efforts on exploring the clinical impact PSMA PET/CT had in the real-life scenario of patients with recurrent prostate cancer. Indeed, an examination is useful if its performance modifies patient management, possibly with an amelioration of his clinical condition and outcome. We found a modification of clinical management in 76% of the men who underwent PSMA PET/CT. Clearly, the long-term impact of the clinical decision made for our patients remains to be demonstrated. Nonetheless, in 57/131 (44%) we have been able to withhold or delay androgen blockage, probably ameliorating their quality of life and not endangering their oncological outcomes [15] . Moreover, although the examination did not literally change the therapeutic strategy in other patients, as in those who were already scheduled for prostatic fossa irradiation (11/131), we think it is reassuring to confirm the proposed approach and target lesion with an imaging examination. This is also helpful in counselling the patient and may reduce useless irradiations or hormonal treatments. A radiotherapy boost to the PSMA-positive lesion could also be administered [32] .
Our present study is not devoid of limitations. Indeed, one could argue that the treatment of oligometastatic disease has not yet proven to yield favourable long-term outcomes for prostate cancer [33] . Nonetheless, delaying hormone therapy is crucial in order to reduce cardiovascular morbidity and mortality [15] . Moreover, the present study is retrospective in nature, thus its results must be interpreted with caution. Although MOC members were blinded to the results of the 68 Ga-PSMA PET/CT when giving the primary treatment choice, the fact of knowing that an additional potentially 'game-changing' test had been performed may have biased our results and increased our rates of treatment modifications. Finally, our present cohort was not homogeneous, as patients underwent different types of primary cancer treatment (surgery, radiotherapy, HIFU); nonetheless, this represents a real-life situation in which every day clinical choices are always applied to a heterogeneous cohort of patients. Adapting our therapeutic decisions according to a more sensitive and specific imaging technique seems the right step for a better personalised therapeutic approach. However, as to whether this approach of treatment decision based on 68 Ga-PSMA PET/CT is beneficial for the patient in terms of overall and progression-free survival is something that needs to be addressed in further large prospective trails.
Conclusions
In this retrospective study, the use of 68 Ga-PSMA PET/CT in the setting of recurrent prostate cancer after local treatment with curative intent determined a modification of planned medical/surgical therapeutic strategy in 76% of patients. These modifications mainly regarded surveillance, hormonal manipulations, stereotaxic radiotherapy and salvage treatments. Further larger and prospective studies are necessary to confirm our present findings.
